Exact Mass: 679.2535

Exact Mass Matches: 679.2535

Found 22 metabolites which its exact mass value is equals to given mass value 679.2535, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

1beta-cis-cinnamoyl-4alpha-hydroxy-5alpha,7beta,11-triacetoxy-8beta-nicotinoyldihydroagarofuran|triptersinine E

C36H41NO12 (679.2629)

mayotamide B

C29H41N7O4S4 (679.2103)

Cys Trp Trp Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C36H37N7O5S (679.2577)

Trp Cys Trp Trp

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C36H37N7O5S (679.2577)

Trp Trp Cys Trp

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C36H37N7O5S (679.2577)

Trp Trp Trp Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanoic acid

C36H37N7O5S (679.2577)

dihydroergotamine mesylate

Dihydro Ergotamine Mesylate

C34H41N5O8S (679.2676)

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents D002491 - Central Nervous System Agents > D000700 - Analgesics Dihydroergotamine mesylate is an ergot alkaloid that can be used for the research of migraines[1][2][3].

Ac-Val-Asp-Val-Ala-Asp-pNA

C29H41N7O12 (679.2813)

Streptomycin sulfate (250mg/ml)

C21H41N7O16S (679.233)

Fibrinogen-Binding Peptide (TFA)

C27H40F3N7O10 (679.2789)

Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin[1].

(2s,8s,15s,18r,22r,25s,26r)-8-benzyl-22-[(2s)-butan-2-yl]-10,17,24-trihydroxy-15,26-dimethyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one

(2s,8s,15s,18r,22r,25s,26r)-8-benzyl-22-[(2s)-butan-2-yl]-10,17,24-trihydroxy-15,26-dimethyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one

C33H41N7O5S2 (679.261)

(2s,8s,15r,18r,22r,25s,26r)-8-benzyl-22-[(2s)-butan-2-yl]-10,17,24-trihydroxy-15,26-dimethyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one

(2s,8s,15r,18r,22r,25s,26r)-8-benzyl-22-[(2s)-butan-2-yl]-10,17,24-trihydroxy-15,26-dimethyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one

C33H41N7O5S2 (679.261)

(2s,8s,15s,22s,26r)-8-benzyl-10,17,24-trihydroxy-15,26-dimethyl-22-(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one

(2s,8s,15s,22s,26r)-8-benzyl-10,17,24-trihydroxy-15,26-dimethyl-22-(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one

C33H41N7O5S2 (679.261)

8-benzyl-10,17,24-trihydroxy-15,26-dimethyl-22-(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one

8-benzyl-10,17,24-trihydroxy-15,26-dimethyl-22-(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one

C33H41N7O5S2 (679.261)

(2s,8s,11r,15s,22s)-10,17,24-trihydroxy-8,22-diisopropyl-15-[2-(methylsulfanyl)ethyl]-13,20,27-trithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,14(30),16,18,21(29),23-heptaen-7-one

(2s,8s,11r,15s,22s)-10,17,24-trihydroxy-8,22-diisopropyl-15-[2-(methylsulfanyl)ethyl]-13,20,27-trithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,14(30),16,18,21(29),23-heptaen-7-one

C29H41N7O4S4 (679.2103)

2-(2,3-dimethyloxiran-2-yl)-5,11-dihydroxy-10-{5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4,6-dimethyl-4-(methylamino)oxan-2-yl}-1-oxatetraphene-4,7,12-trione

C36H41NO12 (679.2629)